deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT05080959

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CPL-01 in Postoperative Pain After Open Inguinal Herniorrhaphy

Sponsor: Cali Pharmaceuticals LLC

Conditions Inguinal Herniorrhaphy
Interventions CPL-01 Naropin 150 MG Per 20 ML Injection Placebo
Updated 6 times since 2021 Last updated: Jul 18, 2022 Started: Jul 28, 2021 Primary completion: Dec 31, 2021 Completion: Jun 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Inguinal Herniorrhaphy and is currently completed. Cali Pharmaceuticals LLC leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshotActive Not Recruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 1 earlier version

  1. Nov 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cali Pharmaceuticals LLC
Data source: Cali Pharmaceuticals LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations